Literature DB >> 15831277

Prevention of hepatocellular carcinoma.

Antonio Craxì1, Calogero Cammà.   

Abstract

The accuracy and the reliability of well-recognized clinical, virologic, histologic, and molecular risk factors for hepatocellular carcinoma are still insufficient; thus, accurate risk prediction of developing cancer in individual patients remains an elusive goal.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15831277     DOI： 10.1016/j.cld.2004.12.008

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  13 in total

Review 1.  Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.

Authors:  Li-Ping Chen; Jun Zhao; Yan Du; Yi-Fang Han; Tong Su; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Virol       Date:  2012-12-12

Review 2.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

3.  Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients.

Authors:  Phimpha Paboriboune; Thomas Vial; Philavanh Sitbounlang; Stéphane Bertani; Christian Trépo; Paul Dény; Francois-Xavier Babin; Nicolas Steenkeste; Pascal Pineau; Eric Deharo
Journal:  Virol Sin       Date:  2018-06-13       Impact factor: 4.327

4.  Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.

Authors:  Anna S Lok; James E Everhart; Elizabeth C Wright; Adrian M Di Bisceglie; Hae-Young Kim; Richard K Sterling; Gregory T Everson; Karen L Lindsay; William M Lee; Herbert L Bonkovsky; Jules L Dienstag; Marc G Ghany; Chihiro Morishima; Timothy R Morgan
Journal:  Gastroenterology       Date:  2010-12-01       Impact factor: 22.682

5.  Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Authors:  Masao Omata; Laurentius A Lesmana; Ryosuke Tateishi; Pei-Jer Chen; Shi-Ming Lin; Haruhiko Yoshida; Masatoshi Kudo; Jeong Min Lee; Byung Ihn Choi; Ronnie T P Poon; Shuichiro Shiina; Ann Lii Cheng; Ji-Dong Jia; Shuntaro Obi; Kwang Hyub Han; Wasim Jafri; Pierce Chow; Seng Gee Lim; Yogesh K Chawla; Unggul Budihusodo; Rino A Gani; C Rinaldi Lesmana; Terawan Agus Putranto; Yun Fan Liaw; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2010-03-18       Impact factor: 6.047

6.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Authors:  Anna S Lok; Leonard B Seeff; Timothy R Morgan; Adrian M di Bisceglie; Richard K Sterling; Teresa M Curto; Gregory T Everson; Karen L Lindsay; William M Lee; Herbert L Bonkovsky; Jules L Dienstag; Marc G Ghany; Chihiro Morishima; Zachary D Goodman
Journal:  Gastroenterology       Date:  2008-09-18       Impact factor: 22.682

Review 7.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 8.  Multimodal approaches to the treatment of hepatocellular carcinoma.

Authors:  Giuseppe Cabibbo; Federica Latteri; Michela Antonucci; Antonio Craxì
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-02-03

9.  Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.

Authors:  Fabian Finkelmeier; Georg Dultz; Kai-Henrik Peiffer; Bernd Kronenberger; Franziska Krauss; Stefan Zeuzem; Christoph Sarrazin; Johannes Vermehren; Oliver Waidmann
Journal:  Liver Cancer       Date:  2018-03-01       Impact factor: 11.740

10.  p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor.

Authors:  B Testoni; V Schinzari; F Guerrieri; S Gerbal-Chaloin; G Blandino; M Levrero
Journal:  Oncogene       Date:  2011-03-14       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.